About DURECT
DURECT is a company based in Cupertino (United States) founded in 1998 by James E. Brown was acquired by Bausch Health in July 2025. The company has 79 employees. DURECT operates in a competitive market with competitors including Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter Cupertino, United States
- Employees 79
- Founders James E. Brown
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website durect.com
- Social LinkedIn X
- Acquired by Bausch Health (Jul 2025)
- Legal Name Durect Corporation
- Annual Revenue$189 K (USD)-93as on Dec 31, 2024
- Net Profit-$8.32 M (USD)70as on Dec 31, 2024
- EBITDA-$18.91 M (USD)52as on Dec 31, 2024
- Investors
- Employee Count79
- Acquired byBausch Health
(Jul 2025)
Investors in DURECT
DURECT has secured backing from 1 investor. Prominent investors backing the company include Bausch Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapeutics for multiple diseases including dermatology and neurology are developed. | 1960 | bauschhealth.com | Laval, Canada |
Investor details for DURECT
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DURECT
29 people are tracked at DURECT (10 in leadership, 5 in board & advisors, 14 in team); the tracked headcount is 79.
| Name | Role | Group |
|---|---|---|
James E. Brown | Co-Founder & CEO | Leadership |
David J. Ellis | VP, Clinical Development | Leadership |
Norman L. Sussman | Chief Medical Officer | Leadership |
Andrew R. Miksztal | VP, Pharmaceutical Research & Development, Principal Scientist | Leadership |
Timothy M. Papp | CFO | Leadership |
George Brown | Sr.director, Corporate Facilities | Leadership |
Charlie Claycomb | Executive Director Information Technology | Leadership |
Alex Haedrich | EHS & Security Associate Director | Leadership |
Susan Autio | Exe. Director Engineering Manufacturing Development & Clinical Packaging | Leadership |
John Gibson | VP Birmingham Operations | Leadership |
Judith J. Robertson | Director | Board & advisors |
Peter Garcia | Director | Board & advisors |
Terrence F. Blaschke | Director | Board & advisors |
Gail M. Farfel | Director | Board & advisors |
Gail J. Maderis | Chair of the Board | Board & advisors |
Weiqi Lin | EVP, Research & Development & Principal Scientist | Team |
Judy Joice | SVP, Operations & Corporate Quality Assurance | Team |
Neil Verity | Exc Dir Pharmacology | Team |
Jian Li | SVP, Finance & Corporate Controller | Team |
Guadalupe Saenz | Sr Accounts Payable Coordinator | Team |
9 more people are available in the full profile.
Complete people profiles for DURECT
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of DURECT
DURECT is a publicly listed company on the NASDAQ with ticker symbol DRRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Sep 2000
- Listed onNASDAQ: DRRX
- Listed entityDURECT Corporation
- Exchange sectorHealth technology
- Share price$1.91 (-1.04% on the day) · 2025-09-12
- Market capitalisation$59.3M
- EPS (diluted, trailing year)$-0.47
- Volume (last session)2,787,659
- Analyst consensusNeutral
Timeline of DURECT
3 dated milestones of DURECT across 27 years, from founding to its latest funding, stage changes and deals.
- Founded DURECT is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Bausch Health.
Competitors of DURECT
DURECT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. |
Detailed competitors of DURECT
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DURECT
The website of DURECT (durect.com) receives about 2.1K visits a month and ranks #8,779,649 among all websites worldwide, #7,485 in Biotechnology and Pharmaceuticals.
- Monthly visits2.1K
▲ 11.6% vs previous month
- Global rank#8,779,649
among all websites
- Category rank#7,485
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.5
- Average visit30 sec
- DevicesDesktop 28% · Mobile 72%
Websites whose visitors overlap most with DURECT. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| supergen.com | 100% | – | – | View details | |
clinicaltrialsregister.eu | clinicaltrialsregister.eu | 91% | – | #523,655 | – |
| astx.com | 90% | 8.9K | #2,592,392 | View details | |
ir.flexiontherapeutics.com | ir.flexiontherapeutics.com | 90% | – | – | – |
elevenbio.com | elevenbio.com | 90% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for DURECT
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Durect
Complete news archive for DURECT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to DURECT
10 companies that operate in the same segment as DURECT (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DURECT
DURECT was founded in 1998.
DURECT is headquartered in Cupertino, United States. It is registered at Cupertino, California, United States.
James E. Brown is the current CEO of DURECT. They have also founded this company.
DURECT has 79 employees.
Annual revenue of DURECT is $189K as on Dec 31, 2024.
Developer of therapeutics for chronic diseases and pain. Commercial products include alzet osmotic pumps and absorbable polymers. It has various drug delivery platforms like a cloud, oradur, and transducer. It utilizes these technologies for its pipeline candidates which include DUR-928or chronic liver disease, posimir in the new drug application stage (NDA) for post-operative pain, remoxy in the NDA stage for chronic pain,.
DURECT's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.
Yes, DURECT is publicly traded on NASDAQ under the ticker symbol DRRX.
DURECT has 1 investor. Key investors include Bausch Health.
Yes. DURECT was acquired by Bausch Health in July 2025.